Monday, May 7, 2012

CDC warning – “Outbreaks of Carbapenem-Resistant Enterobacteriaceae!”

May 2, 2012, Dr. Arjun Srinivasan, from the Centers for Disease Control and Prevention (CDC), warned about new outbreak during spring meeting of Society for Healthcare Epidemiology of America (SHEA) in Florida. The issue is a highly drug-resistant pathogen that causes a growing cases of outbreaks in healthcare facilities, called Carbapenem-Resistant Enterobacteriaceaealso named as CRE. 

Enterobacteriaceae is a large group of gram-negative organisms that are common residents of the gastrointestinal tract. These organisms have been readily treatable with antibiotics, but over the last several years we have encountered a growing number of Enterobacteriaceae that are resistant to all of known antibiotics, including carbapenems. Historically, carbapenems had been our last line of defense in treating Enterobacteriaceae. So, the development of resistance to these last-line agents has been a significant problem in healthcare. Reliable studies have shown that the mortality rate from CRE infections can reach as high as 40%. Thus, CRE pose a major therapeutic dilemma in some facilities now
Additionally, CDC has seen that these organisms can spread very quickly in non-emergency healthcare facilities like ambulatory surgical and long-term care centers
CDC suggests carefully trace each patient when moving from one facility to another, and timely isolation of each CRE case.
AIHD comments: 
Keeping in mind 40% of mortality rate, it's unfortunate that allopathic medicine can’t help much their patients yet. However, there are some hopes. These are Oregano and Melaleuca essential oils. These oils successfully suppress other antibiotic resistant bacteria, like Staph, and MRSA. It could be applied topically or internally, but keep in mind - a protocol of their application has not been established yet, and should be adjusted. If your friend or relative succumb to CRE you may want to contact AIHD as soon as possible. Our phone is (908) 938-3145 and email 

No comments:

Post a Comment